|
October 5, 2007
Helixis, Inc. Announces Advanced Technology Ventures' Role
in Series A Financing
Carlsbad, Calif., October 5, 2007 -
Helixis, Inc., an early-stage company focused on the development of
low-cost, fast and accurate molecular diagnostic products and
research instruments, today announced the participation of Advanced
Technology Ventures (ATV) in the Company's $10 million Series A
round completed in late August, joining Domain Associates and Okapi
Venture Capital.
"We are very pleased to be able
to announce ATV's role in the financing," said Alex
Dickinson, president, chief executive officer and
co-founder, Helixis. "We are now in the fortunate position
of welcoming them publicly to both the Series A syndicate
and our Board."
In conjunction with the ATV
investment, Ken Noonan, PhD, a Venture Partner with ATV, has
joined Helixis' Board of Directors.
"Helixis has the potential to
significantly increase the affordability and availability of
molecular analytic technology in both the laboratory and the
clinic, as well as expand its use to contiguous fields,"
said Tom Rodgers, Principal, Advanced Technology Ventures,
who led the firm's investment in Helixis. "We look forward
to working with Alex and his team to realize this
potential."
About Helixis, Inc.
Helixis, Inc. is an early-stage diagnostics company focused on
the development of low-cost, fast and accurate molecular diagnostic
products. Founded in 2007 by several of the world's most respected
molecular biologists and engineers, the company has a mission to
make advanced molecular diagnostic products more accessible for
critical medical and scientific applications in both the developed
and developing worlds. Helixis is headquartered in Carlsbad, CA. For
more information, visit
www.helixis.com.
|
 |
